Prostate And Other Male Cancers

At a median follow-up of 12 weeks, results showed that the composite response rate was 23%.

The PRESIDE trial included 687 chemotherapy-naïve patients with mCRPC who had progressive disease while on androgen deprivation therapy or following bilateral orchiectomy.

The analysis included 4919 patients, of which 19.7% (n=969) had received a lipophilic statin and 9.2% (n=452) had received a hydrophilic statin.

Following a planned interim analysis, the decision to halt the trial was made after a review of data by an independent Data Monitoring Committee.

Study authors analyzed a total of 46 Black men with advanced prostate cancer enrolled in the phase 3 HERO study.

The phase 3 MAGNITUDE study assessed niraparib in combination with abiraterone acetate plus prednisone in patients with mCRPC with or without alterations in homologous recombination repair associated genes.